Form 4 for PYXS Pyxis Oncology, Inc.
Accepted 2023-09-18 00:00:00 ET · period of report 2023-09-14 · accession 0001209191-23-049826 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-09-18 | 2023-09-14+ | PYXS | Sullivan Lara | Pres, CEO, Dir | S - Sale | $2.10 | -8,641 | 2.40M | -0.4% | -$18.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-14 | S | D | 100 | $2.25 | 2,412,423 | D | — | — | |
| 2 | Common | Common Stock | 2023-09-18 | S | D | 8,541 | $2.10 | 2,403,882 | D | — | — |